AEON Biopharma, Inc.
AEON
$0.69
-$0.0043-0.62%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.46% | -41.17% | -31.06% | -23.84% | 13.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.16% | -57.36% | -47.34% | -40.18% | -15.40% |
| Operating Income | 59.16% | 57.36% | 47.34% | 40.18% | 15.40% |
| Income Before Tax | 99.46% | 134.87% | 110.92% | 103.48% | -291.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 99.46% | 134.87% | 110.92% | 103.48% | -291.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.46% | 134.87% | 110.92% | 103.48% | -291.60% |
| EBIT | 59.16% | 57.36% | 47.34% | 40.18% | 15.40% |
| EBITDA | 59.26% | 57.46% | 47.43% | 40.24% | 15.44% |
| EPS Basic | 98.40% | 144.28% | 115.05% | 103.32% | -796.61% |
| Normalized Basic EPS | 90.40% | 92.41% | -75.83% | -67.46% | -484.34% |
| EPS Diluted | 98.24% | 144.20% | 114.93% | 103.25% | -796.61% |
| Normalized Diluted EPS | 90.41% | 92.42% | -75.80% | -67.46% | -484.34% |
| Average Basic Shares Outstanding | 569.82% | 48.08% | -58.53% | -67.95% | -68.72% |
| Average Diluted Shares Outstanding | 569.86% | 48.10% | -58.51% | -67.95% | -68.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |